Responsiveness and Interpretation of a Quality of Life Questionnaire Specific to Upper Gastrointestinal Disorders

被引：45

作者：

de la Loge, Christine ^{[1
]}

Trudeau, Elyse ^{[1
]}

Marquis, Patrick ^{[2
]}

Revicki, Dennis A. ^{[3
]}

Rentz, Anne M. ^{[3
]}

Stanghellini, Vincenzo ^{[4
]}

Talley, Nicholas J. ^{[5
]}

Kahrilas, Peter ^{[6
]}

Tack, Jan ^{[7
]}

Dubois, Dominique ^{[8
]}

机构：

[1] Mapi Values, F-69003 Lyon, France

[2] Mapi Values, Boston, MA USA

[3] MEDTAP Int Inc, Bethesda, MD USA

[4] Univ Bologna, Dept Internal Med & Gastroenterol, Bologna, Italy

[5] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia

[6] Northwestern Univ, Div Gastroenterol, Chicago, IL 60611 USA

[7] Univ Leuven, Dept Gastroenterol, Louvain, Belgium

[8] Johnson & Johnson Pharmaceut Serv LLC, Beerse, Belgium

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2004年 / 2卷 / 09期

关键词：

D O I：

10.1016/S1542-3565(04)00349-0

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background & Aims: The Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) has been developed and validated to assess quality of life in gastroesophageal reflux disease, dyspepsia, and gastroparesis. The aim of this work was to assess responsiveness of the PAGI-QOL to clinical changes and provide guidance for the interpretation of score changes. Methods: The analysis was based on 2 observational multicenter, longitudinal, 8-week observation studies, one in the United States and one in 5 European countries. The Overall Treatment Effect scale completed by patients and clinicians at 8 weeks was used to define groups of improved, worsened, and stable patients. Responsiveness was assessed by describing the change in PAGI-QOL scores for each of these groups, comparing these changes over time, and calculating effect sizes and standardized response means. These data were used to define the minimal clinically important difference. Results: A total of 1736 patients with upper gastrointestinal disorders were analyzed. High sensitivity to change over time was demonstrated, with effect sizes and standardized response means in improved patients for the PAGI-QOL total score ranging from 0.79-1.41. A change of 0.4 for the PAGI-QOL total score might be considered as the minimal clinically important difference when comparing pretreatment and post-treatment PAGI-QOL total scores. Conclusions: The PAGI-QOL questionnaire is a responsive and clinically relevant instrument for assessing quality of life in patients with upper gastrointestinal disorders.

引用

页码：778 / 786

页数：9

共 17 条

[1]

Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127

[2]

Cohen J., 1988, STAT POWER ANAL BEHA

[3] Defining clinically meaningful change in health-related quality of life [J].